Remnant Cholesterol Captures Residual CV Risk in Patients Wi
Adding to a growing body of evidence that elevated remnant cholesterol (remnant-C) provides additional and independent risk prediction for major cardiovascular events (MACE), a new analysis has this shown this biomarker has prognostic value specifically in patients with type 2 diabetes (T2D).

In a post hoc analysis of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, each standard-deviation increase in remnant-C was associated with a 7% increased risk in MACE after adjustment for several risk factors including other cholesterol values. "In type 2 diabetes, remnant-C levels are associated with MACE regardless of LDL-C," reported investigators.